In a concerning revelation, nearly one-third of the mpox vaccines donated by Japan to the Democratic Republic of Congo (DRC) are reportedly going to waste. The cause? Complex storage and handling requirements that make the vaccine difficult to preserve once opened.
This issue highlights the persistent global challenges in vaccine logistics — particularly in regions facing infrastructural and political instability. It also underscores the need for technological collaboration between global health organizations and the pharmaceutical industry to improve vaccine delivery systems.
Japan’s Donation to Fight the Mpox Outbreak
Japan donated three million doses of its LC16 vaccine to the DRC to help fight the new clade Ib variant of mpox — a strain that triggered a global health emergency last year.
The second batch of 1.5 million doses arrived in September, nearly two years after the outbreak began. Vaccination drives started in Kinshasa in August, and so far, over half a million people have received either LC16 or Bavarian Nordic’s mpox vaccine.
However, as per Cris Kacita, head of Congo’s mpox response, a significant portion of the LC16 doses are being lost during administration. “The loss rate is around 32–35%,” Kacita said. “We’re really doing everything we can to prevent loss.”
Why Are So Many Vaccines Being Wasted?
Each LC16 vaccine vial contains 250 powder doses that must be reconstituted before use. Once mixed, the vaccine cannot be stored for more than a few hours, even under cold-chain conditions.
If turnout at vaccination centers is lower than expected, leftover doses in open vials must be discarded. This leads to high wastage rates, estimated at about one-third of all doses received.
According to World Health Organization (WHO) guidelines, vaccine wastage rates can range from 5% to 50%, with multi-dose formulations like LC16 tending toward the higher end.
Challenges Beyond Storage
Beyond the technical storage issue, Congo faces multiple logistical and regional challenges:
-
Many affected provinces are remote, making vaccine delivery and cold-chain maintenance difficult.
-
Some regions are politically unstable, limiting consistent vaccination efforts.
-
LC16 requires specific needles and techniques, adding further complexity to training healthcare workers.
Despite these challenges, the LC16 vaccine has proven effective in curbing transmission, particularly in Kinshasa, Congo’s capital.
Japan’s Response and Global Context
The Japanese government stated it had not been informed of the wastage issue but expressed confidence in Congo’s efforts to manage vaccine administration effectively.
Globally, vaccine wastage continues to be a major challenge — especially in low-resource settings where cold-chain infrastructure is weak or population turnout is unpredictable.
This situation serves as a reminder of the importance of vaccine formulation innovation, proper planning, and flexible manufacturing partnerships to minimize loss and maximize impact.
Mpox Situation in 2025: The Numbers
According to Congo’s mpox response unit, the country has recorded 53,657 mpox cases this year — a reduction from 67,247 cases in 2024.
Although the World Health Organization downgraded mpox from a global health emergency in September, transmission continues in 17 African countries.
The progress made so far is promising, but sustainable control will depend on better vaccine storage solutions, expanded access to refrigeration, and faster delivery systems to remote areas.
The Role of the Pharma Industry in Addressing Global Health Challenges
Global vaccine management requires robust coordination between governments, healthcare organizations, and the pharmaceutical manufacturing sector.
Companies specializing in pharma contract manufacturing play a vital role here. They ensure that large-scale vaccine production, packaging, and global supply chains meet international safety and storage standards.
By optimizing production and reducing wastage, contract manufacturing companies help bridge the gap between vaccine development and public distribution — ensuring that every vial counts.
Similarly, Indian pharma leaders, particularly those operating as monopoly medicine companies, have shown how localized production and controlled distribution models can minimize waste, lower costs, and ensure efficient medicine availability across regions.
Lessons and the Road Ahead
The vaccine wastage issue in Congo offers key takeaways for the global health community:
-
Improve Cold-Chain Infrastructure: Investing in portable cold storage and solar-powered refrigeration can help preserve vaccines longer.
-
Enhance Training Programs: Healthcare workers need specialized training to handle complex vaccines like LC16.
-
Flexible Dosing and Packaging: Future vaccine designs should include smaller vials to reduce waste.
-
Public Awareness Campaigns: Increasing turnout at vaccination sites can significantly reduce leftover doses.
Collaborative efforts between governments and pharmaceutical companies can transform how the world responds to such outbreaks — ensuring effective vaccine utilization and better healthcare access in the long run.
Conclusion
The wastage of one-third of Japanese mpox vaccines in Congo highlights a critical gap in global vaccine distribution — the storage and handling infrastructure. While Japan’s donation aimed to bolster Congo’s mpox response, technical challenges have limited the program’s efficiency.
To address such issues worldwide, pharmaceutical innovation, effective contract manufacturing, and strategic distribution models are essential. Companies like DM Pharma Global, through their expertise as a pharma contract manufacturing company and leadership among monopoly medicine companies in India, continue to drive solutions that improve medicine availability, reduce waste, and strengthen healthcare systems globally.